Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 1 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0045 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0045 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0044 | 0.9701 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0044 | 0.9701 | 0.9633 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0044 | 0.9701 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0044 | 0.9701 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0019 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1847 | 0.1904 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0045 | 1 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0044 | 0.9701 | 0.9633 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1847 | 0.1904 |
Leishmania major | DNA polymerase eta, putative | 0.0031 | 0.5597 | 0.4775 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0031 | 0.5597 | 0.4775 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 0.1847 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Schistosoma mansoni | DNA polymerase eta | 0.0044 | 0.9701 | 0.9633 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0019 | 0.1847 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0044 | 0.9701 | 0.9633 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.1847 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0045 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.0044 | 0.9701 | 0.9633 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Giardia lamblia | DINP protein human, muc B family | 0.0019 | 0.1847 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0019 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0045 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0019 | 0.1847 | 0.1904 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 1 | 1 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0031 | 0.5597 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0019 | 0.1847 | 0.1904 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0019 | 0.1847 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0019 | 0.1847 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.168 ug ml-1 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate Alamar blue assay | ChEMBL. | 22931472 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.